Januvia approved as add-on to insulin treatment

Januvia (sitagliptin) can now be prescribed as an add-on to insulin (with or without metformin) for patients with type II diabetes in whom diet and exercise, plus a stable dose of insulin, do not provide adequate glycaemic control. In a 24-week study in 305 patients, addition of sitagliptin to insulin significantly improved glycaemic parameters compared with placebo, with no major effect on body weight. When Januvia is combined with insulin, reduction of the insulin dose may be appropriate to reduce the risk of hypoglycaemia.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A healthcare professional holds a syringe in one hand while pinching a baby's thigh as they prepare to administer a vaccination.

Changes to routine vaccination schedule recommended by JCVI

The Joint Committee on Vaccination and Immunisation...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...